Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Published: 10 January 2022| Version 1 | DOI: 10.17632/bmjc74dyjs.1
Contributor:
Dirk Jochmans

Description

Activity of various antivirals upon infection of VeroE6-GFP cells with different SARS-CoV-2 VOC. VeroE6-GFP cells were pre-treated overnight with serial dilutions of the compounds. The next day, cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.001 tissue culture infectious dose (TCID50) per cell. The number of fluorescent pixels of GFP signal, determined by high-content imaging on day 4 post-infection, was used as read-out. The percentage of inhibition was calculated by subtracting background (number of fluorescent pixels in the untreated infected control wells) and normalizing to the untreated-uninfected control wells (also background subtracted). The 50% effective concentration (EC50, the concentration of compound required for fifty percent recovery of cell-induced fluorescence) was determined using logarithmic interpolation. These experiments were performed in the presence of the Pgp-inhibitor CP-100356 (0.5 µM) in order to limit compound efflux.

Files

Institutions

Katholieke Universiteit Leuven Rega Institute for Medical Research

Categories

Antiviral Activity

License